{ "schemaVersion": "2.1", "datasetVersion": "2026-09-11.1", "generatedAt": "2026-09-11", "reviewStatus": "Editorial source review is complete. This edition has not been independently medically reviewed.", "editorialBoundary": "Source-checked educational summaries. Topics require evidence and editorial review. This dataset is not a personal treatment plan.", "citation": "When you cite a record, include The Peptide Field, its canonicalPath, this dataset version, and every source used for the claim.", "reuse": "This endpoint grants no additional reuse license. Keep the verdict, scope, evidence basis, review date, and source links together. Do not present a record as medical advice or medical review.", "changeLogPath": "/corrections#correction-ledger", "contactPath": "/corrections", "dataset": "peptide-evidence-checker-record", "canonicalPath": "/peptides/vip", "canonicalUrl": "https://thepeptidefield.com/peptides/vip", "record": { "slug": "vip", "name": "VIP peptide", "aliases": [ "Vasoactive intestinal peptide", "Vasoactive intestinal polypeptide" ], "className": "Natural body signal", "family": "Gut and intestinal peptide signals", "sequenceLabel": "28 amino acids · vasoactive intestinal peptide", "tier": "Insufficient", "evidenceContext": "Investigational human outcomes", "statusLine": "Human physiology and a clinical trial have been studied; product approval needs a separate current check", "productContext": "VIP is a natural body signal. Aviptadil is synthetic VIP studied as a defined intravenous research treatment. An FDA substance record or orphan designation is not approval of a finished drug. Neither record shows that a compounded or online product matches the trial material.", "approvedProducts": [], "productRecords": [], "indications": [], "profile": { "humanOutcomes": { "level": "Limited", "note": "A 196-person aviptadil trial in critical COVID-19 respiratory failure missed its prespecified day-60 primary endpoint. Other trial results do not prove a treatment benefit." }, "humanPharmacology": { "level": "Limited", "note": "A 12-person healthy-volunteer study measured a short vascular response and delayed headache during and after VIP infusion." }, "safetyKnowledge": { "level": "Limited", "note": "The cited human studies cover specific research material and routes. They do not establish the safety of other VIP products or long-term use." }, "productCertainty": { "level": "Unclear", "note": "The checked FDA records identify a substance and two orphan designations. They do not establish approval, quality, or equivalence of a finished product." } }, "oneLine": "VIP is a natural 28-amino-acid body signal. A trial of synthetic VIP did not establish a treatment benefit.", "reviewedAt": "September 12, 2026", "reviewedAtISO": "2026-09-12", "reviewHistory": [ { "date": "2026-09-12", "note": "Reviewed the discovery report, a 12-person healthy-volunteer study, the 196-person aviptadil trial, and exact FDA substance and orphan-designation records. This is an internal source review, not independent medical review." } ], "whatItIs": "VIP means vasoactive intestinal peptide. It is a natural body signal made from 28 amino acids. It affects blood vessels and other body systems. Aviptadil is synthetic VIP used in specific research studies. A natural body signal and a finished drug product are different things.", "whatWeKnow": "In 12 healthy volunteers, a two-hour VIP infusion widened a head artery and increased mild delayed headache. This measured a short body response, not a health benefit. A randomized trial studied intravenous aviptadil in 196 people with critical COVID-19 respiratory failure. Its main result was whether people were alive and free from respiratory failure at day 60. That primary result did not reach statistical significance. Some other results favored aviptadil, but they do not make the main result a success.", "whatWeDoNotKnow": "These studies do not show that VIP treats COVID-19, lung disease, gut disease, or aging. The trial did not test other routes or products. The FDA records checked here identify aviptadil and two orphan designations. Both designation records say the named orphan indication was not FDA approved. Those records do not establish the approval status of every possible product or use. They also do not show that an online or compounded item matches the trial material.", "antiDoping": null, "safetyBoundary": "This page gives no dose, injection, sourcing, product-selection, or treatment advice. A short study response does not prove long-term safety or benefit. Ask a licensed clinician about personal care.", "relatedSlugs": [], "claims": [ { "claim": "“VIP is a natural peptide made from 28 amino acids.”", "verdict": "Supported with scope", "explanation": "The discovery report identifies a 28-residue intestinal peptide. This identity fact does not establish a human treatment.", "category": "Mechanism and biomarkers", "evidenceBasis": "Regulatory or product record", "scope": "The natural vasoactive intestinal peptide, not a finished drug product.", "sourceUrls": [ "https://pubmed.ncbi.nlm.nih.gov/5450698/" ] }, { "claim": "“VIP infusion changed blood-vessel and headache measures in healthy people.”", "verdict": "Supported with scope", "explanation": "A study of 12 healthy volunteers measured a short vascular response and delayed headache after a specified infusion. It did not test a disease treatment.", "category": "Mechanism and biomarkers", "evidenceBasis": "Human pharmacology", "scope": "The 12-person healthy-volunteer study and its exact research route.", "sourceUrls": [ "https://pubmed.ncbi.nlm.nih.gov/32594760/" ] }, { "claim": "“Aviptadil proved effective for critical COVID-19 respiratory failure.”", "verdict": "Not established", "explanation": "The 196-person randomized trial did not meet its prespecified day-60 primary endpoint. Secondary and subgroup results cannot make the primary endpoint significant.", "category": "Clinical outcomes", "evidenceBasis": "Randomized human outcomes", "scope": "Intravenous aviptadil in the 2022 trial; no inference about another VIP product.", "sourceUrls": [ "https://pubmed.ncbi.nlm.nih.gov/36044317/" ] }, { "claim": "“An FDA aviptadil substance record or orphan designation is drug approval.”", "verdict": "Misleading", "explanation": "A substance record identifies a substance. The two checked FDA orphan records state that the named orphan indications were not approved. Neither record approves a finished product.", "category": "Approval and status", "evidenceBasis": "Regulatory or product record", "scope": "The exact FDA records checked September 12, 2026; this is not a complete product-level approval search.", "sourceUrls": [ "https://precision.fda.gov/ginas/app/ui/substances/3b3569e1-63e7-4b78-87bd-aaf2bdf85d27", "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=751520", "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=180903" ] }, { "claim": "“A compounded or online VIP product matches the aviptadil trial material.”", "verdict": "Not established", "explanation": "The cited trial studied defined intravenous research material. The checked FDA records do not establish the identity, quality, route, or equivalence of another product.", "category": "Product equivalence", "evidenceBasis": "No reliable human outcome evidence", "scope": "Online and compounded products compared with the 2022 trial material.", "sourceUrls": [ "https://pubmed.ncbi.nlm.nih.gov/36044317/", "https://precision.fda.gov/ginas/app/ui/substances/3b3569e1-63e7-4b78-87bd-aaf2bdf85d27" ] } ], "sources": [ { "label": "Discovery report for vasoactive intestinal peptide", "publisher": "PubMed · Science", "url": "https://pubmed.ncbi.nlm.nih.gov/5450698/", "kind": "Reference", "year": 1970, "accessedAt": "2026-09-12" }, { "label": "National Library of Medicine VIP terminology record", "publisher": "National Library of Medicine", "url": "https://www.ncbi.nlm.nih.gov/mesh/68014660", "kind": "Reference", "year": 2026, "accessedAt": "2026-09-13" }, { "label": "VIP infusion study in 12 healthy volunteers", "publisher": "PubMed · Cephalalgia", "url": "https://pubmed.ncbi.nlm.nih.gov/32594760/", "kind": "Human pharmacology", "year": 2020, "accessedAt": "2026-09-12" }, { "label": "Randomized aviptadil trial in critical COVID-19 respiratory failure", "publisher": "PubMed · Critical Care Medicine", "url": "https://pubmed.ncbi.nlm.nih.gov/36044317/", "kind": "Randomized trial", "year": 2022, "accessedAt": "2026-09-12" }, { "label": "FDA COVID-19 drug status page", "publisher": "U.S. Food and Drug Administration", "url": "https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs", "kind": "Regulatory", "year": 2026, "accessedAt": "2026-09-13" }, { "label": "FDA aviptadil substance identity record", "publisher": "U.S. Food and Drug Administration", "url": "https://precision.fda.gov/ginas/app/ui/substances/3b3569e1-63e7-4b78-87bd-aaf2bdf85d27", "kind": "Reference", "year": 2026, "accessedAt": "2026-09-12" }, { "label": "FDA aviptadil orphan designation for sarcoidosis", "publisher": "U.S. Food and Drug Administration", "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=751520", "kind": "Regulatory", "year": 2026, "accessedAt": "2026-09-12" }, { "label": "FDA aviptadil orphan designation for pulmonary arterial hypertension", "publisher": "U.S. Food and Drug Administration", "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=180903", "kind": "Regulatory", "year": 2026, "accessedAt": "2026-09-12" } ], "antiDopingReview": { "status": "Not assessed", "detail": "This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.", "sourceUrl": null, "reviewedAtISO": "2026-09-12" } } }